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Purpose: Treating early-onset scoliosis (EOS) with traditional growing rods (TGR) is effective 
but requires periodic surgical lengthening, risking complications. Alternatives include magneti-
cally controlled growing rods (MCGR) that lengthen noninvasively and the growth guidance 
system (GGS), which obviate the need for active, distractive lengthenings. Previous studies have 
reported promising clinical effectiveness for GGS; however the direct medical costs of GGS 
compared to TGR and MCGR have not yet been explored. 
Methods: To estimate the cost of GGS compared with MCGR and TGR for EOS an economic 
model was developed from the perspective of a US integrated health care delivery system. Using 
dual-rod constructs, the model estimated the cumulative costs associated with initial implanta-
tion, rod lengthenings (TGR, MCGR), revisions due to device failure, surgical-site infections, 
device exchange, and final spinal fusion over a 6-year episode of care. Model parameters were 
from peer-reviewed, published literature. Medicare payments were used as a proxy for provider 
costs. Costs (2016 US$) were discounted 3% annually. 
Results: Over a 6-year episode of care, GGS was associated with fewer invasive surgeries per 
patient than TGR (GGS: 3.4; TGR: 14.4) and lower cumulative costs than MCGR and TGR, 
saving $25,226 vs TGR. Sensitivity analyses showed that results were sensitive to changes in 
construct costs, rod breakage rates, months between lengthenings, and TGR lengthening set-
ting of care.
Conclusion: Within the model, GGS resulted in fewer invasive surgeries and deep surgical site 
infections than TGR, and lower cumulative costs per patient than both MCGR and TGR, over a 
6-year episode of care. The analysis did not account for family disruption, pain, psychological 
distress, or compromised health-related quality of life associated with invasive TGR lengthenings, 
nor for potential patient anxiety surrounding the frequent MCGR lengthenings. Further analyses 
focusing strictly on current generation technologies should be considered for future research.
Keywords: early-onset scoliosis, cost analysis, growth guidance system, magnetically controlled 
growing rod, traditional growing rod
Introduction
Early-onset scoliosis (EOS) is defined as a coronal curvature of the spine exceeding 
10° occurring before the age of 10 years, and can be subcategorized as congenital, 
idiopathic, syndromic, or neuromuscular.1–4 Left untreated, EOS may progress to pro-
duce disfigurement and deformity of the chest wall, leading to thoracic insufficiency 
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syndrome characterized by labored breathing, extreme 
breathlessness/fatigue, and reduced quality of life.3 Treatment 
options for EOS include observation, casting, bracing, and 
surgical techniques.3 Ideally EOS treatment would permit 
correction (partial or complete) of the deformity, maintain 
the deformity correction, and permit vertical growth of the 
spine and radial expansion of the rib cage. Fusion surgeries 
result in iatrogenic limitation of spinal growth with long-term 
impairment of pulmonary volumes, making these surgeries 
suboptimal in EOS.5 Hence “growth-friendly” surgeries 
such as growth guidance system (GGS), magnetically con-
trolled growing rods (MCGR), and traditional growing rods 
(TGR) have been developed to attempt to satisfy the goals 
of treatment. 
TGR are effective, yet require periodic invasive surgical 
lengthenings with risk of complications.6 The surgeries inher-
ent with TGR treatment are also associated with considerable 
socioeconomic, psychological, and health-related quality of life 
(HRQoL) disadvantages for both patients and their caregivers.7 
MCGR have also been shown to be clinically effective and can 
be lengthened noninvasively, with a hand-held external remote 
controller, allowing for magnetically controlled continuous 
elongation (to a set tension), or incremental elongation (to a set 
distance).7–12 Although device costs for MCGR are higher, sev-
eral studies have shown that these may be offset by the reduced 
complications and costs garnered by noninvasive lengthen-
ings.13–16 Both TGR and MCGR are effective for preventing 
disease progression and facilitating correction of curves.8–10,12,17,18
An alternative construct for EOS, GGS (SHILLA™ 
Growth Guidance System, Medtronic Spinal & Biologics, 
Memphis, TN, USA) was cleared for marketing in the United 
States in July 2014.19 GGS is a new growth-sparing technol-
ogy that helps provide deformity correction while allowing 
continued skeletal growth at the proximal and distal construct 
ends and obviating the need for periodic lengthening pro-
cedures. GGS utilizes a unique non-locking set screw that 
allows the pedicle screws to slide along the rod axis during 
vertical growth. Once implanted during a surgical procedure 
similar to TGR and MCGR, GGS has demonstrated clinical 
effectiveness (in both curve correction and increasing tho-
racic height) with 6-year follow-up.20,21 Obviating the need for 
invasive lengthening procedures, GGS would be expected to 
reduce overall costs per patient in a similar manner to MCGR; 
however, no economic study of GGS has been published to 
date. The objective of this research was to estimate – over 
a 6-year episode of care – the cumulative cost of treating 
EOS with GGS compared with MCGR and TGR from the 
US integrated health care delivery system (IDS) perspective.
Materials and methods
Model overview
Similar to the cost analysis by Polly et al14 comparing MCGR 
with TGR, the present economic model was developed from 
the IDS perspective. For each treatment using dual-rod 
constructs, the model assessed the 6-year cumulative costs 
associated with initial implantation, rod lengthenings (TGR 
every 6 months; MCGR every 3 months), revisions due to 
device failure, surgical site infections (SSIs), device exchange 
(at 3.8 years), and final spinal fusion. Costs are presented 
in 2016 US$ and, in line with the recommendation of the 
Congressional Budget Office, were discounted at an annual 
rate of 3.0%.22 An institutional review board (IRB) exemption 
was granted given that model parameters were sourced from 
peer-reviewed, published literature and the present research 
did not involve human subjects. 
For the present study, the cost analysis by Polly et al14 
was first reconstructed (from the publicly available paper and 
technical report) and then updated to reflect the most recent 
published literature and to include GGS. As such, the model 
assumptions and parameter values for TGR and MCGR are 
largely based on Polly et al with the exception of updating the 
construct type (to 100% dual-rod to reflect current practice), 
device failure rates, deep SSI rates, time under anesthesia, 
and reimbursement codes and costs. For completeness, we 
have summarized the assumptions and data sources in the 
following section.
Model assumptions and data sources
Table 1 details the model framework created and clinical 
parameters used, while medical resources are detailed in 
Table 2. Importantly, the TGR device failure rates (rod 
breakage rates) were derived from an economic evaluation 
commissioned by the National Institute for Health and Care 
Excellence,18,23 while the MCGR and GGS rod breakage rates 
were obtained from the most recent comparable literature 
available from multicenter studies.11,20 The device failure rates 
for TGR and MCGR were corrected using the relative risk 
of rod breakage for single vs dual-rods to estimate what the 
rate would be if every construct were a dual-rod construct 
(constructs were 64% and 85% dual-rod [P Hosseini and J 
Pawelek, San Diego Spine Foundation, personal communica-
tion, April, 2017] in the sources used for TGR and MCGR, 
respectively).11,18,23,24 The source used for the GGS rod break-
age rate already reflected 100% dual-rod construct.20
The model assumes GGS, MCGR, and TGR are of equal 
clinical effectiveness and that medical resource use for initial 
implantations, revisions, and exchanges with GGS, MCGR, 
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and TGR is similar (with the exception of anesthesia time 
and device cost, where appropriate). The model also assumes 
that one radiograph is required per insertion, health care 
 professional (HCP) visit (GGS), lengthening procedure 
(MCGR and TGR), exchange, revision, deep SSI, and final 
fusion; and treatment of deep SSIs will require intravenous 
Table 1 Model framework and clinical parameters
Parameter Base case value 
(sensitivity analysis [range])
Reference
Model framework
Time horizon (years) 6 (1–6) 14, 20
Size of cohort Per patient NA
Per 1,000 patients
Payer mix
Private payer (%) 51.5 (0–100) 25, 26
Medicaid (%) 48.5 (0–100)
Discount rate (% per annum) 3.00 (0.00–5.00) 22
TGR lengthening setting of care
Hospital outpatient/inpatient (%) 45.8 (0–100)/54.2 (100–0) 14
Hospital inpatient 1-day short stay (%) 55.5 14
Hospital inpatient standard ward (%) 35.2
Hospital inpatient ICU (%) 9.3 14
MCGR lengthening setting of care
Physician office (%) 100.0 a
GGS HCP visit setting of care
Physician office (%) 100.0 a
Device failuresb and SSIs
TGR device failure (% per month) 0.55 (0.27–1.10) 18, 23, 24
MCGR device failure (% per month) 0.56 (0.28–1.13) 11, 24
GGS device failure (% per month) 0.61 (0.30–1.21) 20
Device failure, dual vs single rod (RR) 0.92 (0.46–1.00) 24
Device failures requiring complete removal (vs partial) (%) 5.8 (2.9–11.6) 14, 24
TGR deep SSI (% per invasive surgery) 2.99 (1.49–5.97) 27
MCGR deep SSI (% per invasive surgery) 1.45 (0.72–2.90) 11
GGS deep SSI (% per invasive surgery) 2.24 (1.12–4.48) 28
SSI: Medicaid patients (vs all other patients) (RR) 2.06 (1.19–3.58) 29
Notes: aClinical advisors. bRod breakage.
Abbreviations: GGS, growth guidance system; HCP, health care professional; ICU, intensive care unit; MCGR, magnetically controlled growing rod; NA, not applicable; RR, 
relative risk; SSI, surgical site infection; TGR, traditional growing rod.
Table 2 Resource use
Parameter Base case value 
(sensitivity analysis [range])
Reference
Months between TGR lengthenings 6.0 (6–12) 17
Months between MCGR lengthenings 3.0 (1–6) 18, 23
Months between GGS HCP visits 6.0 (3–9) 30
Years to implant exchange 3.8 (3–5) 31, 32
Implantation
Wedding band use for TGR (% of surgeries) 28.0 14
Tandem connector use for TGR (% of surgeries) 67.0 14
Cross link use for TGR (% of surgeries) 86.0 14
Cross link use for MCGR (% of surgeries) 86.0 14
Cross link use for GGS (% of surgeries) 100.0 30
Partial revision (TGR, MCGR, GGS)
Pedicle screw/hook replacement (% of surgeries) 95.0 14, 24a
Rod set screws replacement (% of surgeries) 61.0 14, 24a
All other components (% of surgeries) 100.0 14, 24a
Note: aClinical advisors. 
Abbreviations: GGS, growth guidance system; HCP, health care professional; MCGR, magnetically controlled growing rod; TGR, traditional growing rod.
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antibiotics and a complete replacement of implants while 
treatment of superficial infections will require oral antibiot-
ics. As the cost of oral antibiotics would be incurred by the 
patient (rather than the provider), this has not been included 
in the analysis; there is also no consideration of pediatric 
mortality. Using the average observed spinal growth in a 
child with EOS aged 6 years; the model estimates that all 
patients will require one surgery to exchange the device at 
3.8 years.31,32 
The components that require replacement during the 
course of a partial revision procedure (Table 2) were based on 
the TGR study by Bess et al and expert clinical advice.14,24 In 
the absence of such data for GGS and MCGR, these percent-
ages have been assumed to be the same for GGS, MCGR, and 
TGR. Hence, during a partial removal for GGS, MCGR, or 
TGR, pedicle screw/hooks were assumed to require replace-
ment in 95% of surgeries, rod set screws in 61% of surgeries, 
and all other components (including rods and connectors) in 
100% of surgeries.
MCGR rod costs were not included for revisions due to 
MCGR failure within 1 year following an MCGR implanta-
tion or MCGR exchange (in the unlikely event of a manufac-
turing defect); all other costs for the MCGR revisions were 
included (for example, cross link, hospital facility costs, and 
professional fees).
Medicare payments were used as a proxy for provider 
costs (a widely accepted methodology for cost analyses).33 As 
such, hospital inpatient facility costs were based on Medicare 
diagnosis-related group (DRG) data, physician professional 
fees were based on current procedural terminology (CPT) 
data, and hospital outpatient facility costs were based on 
ambulatory payment classification (APC) data. As hospital 
inpatient DRG payments are bundled to include the TGR 
device cost, such inpatient procedures for GGS and MCGR 
had the TGR device costs subtracted and the GGS or MCGR 
device costs added in order to account for the differences in 
device costs. Table 3 details the total costs used for these 
procedures in the model, while the Supplementary materials 
detail the component costs, including all CPT, APC, and DRG 
codes and costs, as well as anesthesia, intraoperative neuro-
physiological monitoring, and radiograph codes and costs. 
Sensitivity and scenario analyses were conducted to 
assess whether the cost analysis results were robust to modi-
fications in the values of important parameters such as device 
failure rates, time between lengthenings, and construct costs. 
Results
Base-case results
For a single patient over the 6-year episode of care, GGS 
was associated with fewer invasive surgeries than TGR and 
comparable invasive surgeries to MCGR (GGS: 3.4; MCGR: 
3.4; TGR: 14.4). Simulating 1,000 patients with EOS over the 
6-year episode of care, deep SSIs were substantially lower 
for GGS and MCGR than for TGR (GGS: 83; MCGR: 75; 
TGR: 652), whereas rod breakages per 1,000 patients were 
slightly lower for MCGR and TGR than for GGS (GGS: 436; 
MCGR: 406; TGR: 395).
Figure 1 illustrates the cumulative costs for treatment of 
EOS with GGS compared with MCGR and TGR, detailing 
the higher cost of initial insertion and exchange (at 3.8 years) 
for GGS being offset by the cost of frequent TGR surgical 
lengthenings and associated deep SSIs. From the IDS per-
spective, the 6-year cumulative cost for GGS was lower than 
TGR, saving US$25,226.
Table 3 Total costs used in the model (2016 US$)
Parameter Base case values (sensitivity analysis [range])
TGR MCGR GGSa
Construct 15,229 
(11,421–19,036)c
47,716 
(35,787–59,645)c
33,456b
(25,092–41,820)c
Insertiond 36,653 69,140 55,054
Lengthening 6,466e 270 NA
HCP visit NA NAf 272
Exchanged 13,519 46,007 31,746
Complete revisiond 13,519 46,007 31,746
Partial revisiond 12,276 44,763 30,503
Deep SSId 13,519 46,007 31,746
Removal and final fusion 38,272 38,272 39,330
Notes: aClinical advisors. bMedtronic Spinal & Biologics. cConstruct sensitivity analysis ranges are ±25%. dConstruct costs included. eWeighted mean of inpatient and 
outpatient procedures. fPhysician professional fee is included above in MCGR lengthening in the physician office. Data from Polly et al.34
Abbreviations: GGS, growth guidance system; HCP, health care professional; MCGR, magnetically controlled growing rod; NA, not applicable; SSI, surgical site infection; 
TGR, traditional growing rod.
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Sensitivity analysis
One-way sensitivity analyses indicated that results were 
sensitive to changes in construct costs, rod breakage rates, 
months between lengthenings (TGR and MCGR), and 
TGR lengthening setting of care (Figures 2 and 3). Only 
one parameter in the sensitivity analysis (months between 
lengthenings for TGR) produced a positive budget impact for 
GGS, suggesting that GGS is likely to be cost saving over a 
6-year episode of care from the IDS perspective. Note that 
GGS becomes cost neutral with TGR if TGR lengthenings 
occur at approximately every 9 months.
Using clinically realistic scenarios, two-way sensitivity 
analysis for particularly impactful and less precisely known 
model parameters, specifically 1) GGS with TGR or MCGR 
device failure rates, and 2) months between GGS HCP visits 
with months between TGR or MCGR lengthenings, demon-
strated that the cumulative costs varied by relatively little, 
suggesting that the economic model is robust to plausible 
parameter values (Tables 1 and 2 show ranges). Only when 
TGR lengthenings are performed at 9-month or greater inter-
vals is there a positive budget impact, suggesting that GGS 
is likely to be cost saving over the 6-year episode of care.
Scenario analyses (that is, multi-way sensitivity analyses) 
were also run, to further assess the device failure rate (rod 
breakage rate) – first all the rates for all three technologies 
were set to 0.5493% per month, to reflect the adjusted, dual-
rod rate for TGR from The National Institute for Health and 
Care Excellence (NICE) external assessment report and the 
longest follow-up for the greatest number of patients.18,23 This 
had a minimal impact on costs, reducing the 6-year cumula-
tive costs for GGS and MCGR by less than 1%. The second 
scenario analysis set the values for TGR and MCGR to the 
lowest found in published literature and the GGS to the high-
est (GGS: 0.6053% [represents dual-rod construct]; MCGR: 
Figure 1 Cumulative cost per patient (2016 US$) over six-year episode of care.
Abbreviations: GGS, growth guidance system; MCGR, magnetically controlled growing rods; SSI, surgical site infection; TGR, traditional growing rods.
TGR
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0.3188% [after adjusting for 100% dual-rod construct]; TGR: 
0.3905% [after adjusting for 100% dual-rod construct]). This 
reduced the 6-year cumulative costs for MCGR by approxi-
mately 3% and for TGR by 1%; however, GGS remained cost 
saving compared to both MCGR and TGR.
Discussion
Modeling is a simplified representation of the real world in 
an analytical framework to help decision-makers (patients, 
providers, and payers) compare alternative options in terms 
of their clinical benefit and cost. The present study addresses 
the growing need to demonstrate how medical technologies 
fit into the emerging value-based paradigm. To this end, a 
model was developed to evaluate the clinical-economic value 
of GGS compared to TGR and MCGR. 
The economic model presented in this study demonstrates 
that the cost impact of GGS due to increased construct cost 
(vs TGR) and slightly higher revision rate due to device 
failure (vs TGR and MCGR) is offset by obviating the need 
for repeated surgeries to lengthen TGR (with associated 
deep SSIs). The reduction in costs was mainly driven by 
the absence of inpatient stay, anesthesia, and intraoperative 
neurophysiological monitoring associated with invasive TGR 
lengthenings. As seen in Figure 1, GGS becomes cost sav-
ing in the second year following implantation and remains 
so throughout the remainder of the 6-year episode of care. 
Figure 2 One-way sensitivity analysis of cumulative cost savings per patient (GGS vs TGR; 2016 US$)
Abbreviations: GGS, growth guidance system; HCP, health care professional; SSI, surgical site infection; TGR, traditional growing rods.
–US$60,000
Months between GGS HCP visits
Percentage of medicaid patients
GGS less
expensive than TGR
GGS more
expensive than TGR
TGR device failure rate (rod breakage)
TGR deep SSI rate
TGR construct cost
GGS device failure rate (rod breakage)
Years until exchange
Months between TGR lengthenings
GGS construct cost
Percentage of TGR outpatient lengthenings
Upper bound value Lower bound value
–US$40,000 –US$20,000 US$20,0000
Figure 3 One-way sensitivity analysis of cumulative cost savings per patient (GGS vs MCGR; 2016 US$)
Abbreviations: GGS, growth guidance system; HCP, health care professional; MCGR, magnetically controlled growing rods; SSI, surgical site infection.
Annual discount rate
–US$60,000 –US$40,000 –US$20,000 US$20,0000
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Hence, despite the added expense of the GGS construct 
 compared to the TGR construct, the cost offsets for GGS from 
obviating the need for repeated surgical lengthenings with 
risk of complications appear to financially justify use of GGS.
Of note, substituting the original values from the Polly et al 
paper and technical appendix into this model provides very 
similar costs to those reported in Polly et al, only differing 
by ~1.5%; while the number of deep SSIs, invasive surgeries, 
and device failures per thousand patients align perfectly.14 This 
suggests that the model employed is reproducible.
Compared to MCGR, GGS had a similar number of 
device failures (rod fractures) and deep SSIs; however the 
reduced construct cost for GGS drove cost savings at implan-
tation and exchange as well as after a device failure or deep 
SSI. Previous economic analyses showed cost savings or cost 
neutrality for MCGR vs TGR, which could be reflective of 
the shorter time horizon with lack of exchange,13,16 or the less 
expensive single-rod construct used in 15% of patients.14 We 
believe that our approach is most reflective of current practice 
with dual-rod construct and represents a realistic 6-year time 
horizon, considering the average length of treatment.
As a cost analysis, rather than cost-effectiveness analysis, 
this model did not account for family disruption, pain, psy-
chological distress, implications of multiple anesthetics, or 
compromised HRQoL associated with invasive TGR lengthen-
ings, nor for patient anxiety surrounding the frequent MCGR 
lengthenings. Additionally, recent literature has reported that 
an increased number (eight or more) of invasive surgeries in 
patients with TGR is significantly correlated with an even higher 
rate of complications.27 There could therefore be substantial 
additional direct and indirect cost savings associated with the 
use of GGS compared to TGR. Further, the model does not 
include instances where the MCGR rod fails to lengthen (as 
reported by Choi et al in two of 54 patients), possibly underes-
timating costs of revision surgery; current recommendations 
are to reattempt lengthening at a later date and if that fails, 
replacing the device.11,12 Lastly, due to conflicting views on the 
necessity of revision for hook dislodgement and screw pull-out 
complications, these have not been included in the model. While 
revision costs may therefore be slightly underestimated, they 
currently only account for 9.1%, 7.5%, and 2.8% of total costs 
for GGS, MCGR, and TGR, respectively, and slight variations 
are unlikely to affect the budget impact trend of the model.
Also noteworthy, the Centers for Medicare and Medicaid 
Services (CMS) approved MCGR for a new technology add-
on payment (NTAP) for fiscal year (FY) 2017 in the amount 
of US$15,750, whereby CMS provides incremental payment 
(in addition to the DRG payment) for technologies that qualify 
for NTAP.35 The NTAP payment mechanism is based on the 
cost to hospitals for the new technology and lasts for 2–3 years 
until data are available to reflect the cost of the technology 
in the DRG weights through recalibration. However, NTAP 
applies only to Medicare patients, of whom <2,000 are under 
18 years, meaning that it is unlikely that a Medicare patient 
would be diagnosed with EOS, a disease that affects fewer 
than one in 10,000 people.36,37 For this reason, and the fact that 
CMS is proposing to discontinue NTAP for MCGR for FY 
2018, we did not account for the NTAP in this cost analysis.35
Limitations
While the model parameter values were based on the most 
recent published literature, these reports nevertheless reflect 
various rod materials and diameters. This is particularly rel-
evant for TGR, for which 3.5, 4.5, and 5.5 mm rods of steel 
and titanium in both single- and dual-rod constructs were 
reported in the NICE external assessment report.18,23 This 
limitation was addressed by adjusting the TGR rod fracture 
rate using the relative risk of rod fracture for single- vs dual-
rod construct reported by Bess et al.24 Further, the data used 
herein for MCGR represented a mixture of both first- and 
second- generation devices, whereby the second genera-
tion incorporates structural and mechanism improvements 
intended to reduce device failures. These MCGR data also 
had a limited length of follow-up (mean of 19.4 months) and a 
slightly smaller population (54 patients) than that reported for 
MCGR in the NICE external assessment report (80 patients 
across eight studies) but was taken from a multicenter study 
of five centers, rather than a collection of smaller studies 
and had a higher proportion of dual-rod constructs better 
reflecting current practice.11,18,23 The relatively short follow-
up compared to GGS (6 years) and TGR (4 years) may have 
inflated the MCGR device failure rate slightly. 
Similarly, compared to the original GGS technique that 
used 3.5 mm rods through 2008, the current GGS technique 
uses larger rods, deeper screw placement, c-clamps to pre-
vent migration in the event of rod breakage, and O-arm or 
other image guidance. The rod breakage rate for GGS came 
from a relatively small sample size (18 patients); however 
these data were chosen because they are the most reflective 
of current practice and patients were followed for six years 
through definitive treatment.20 While the GGS device failure 
rate represents a key model parameter, to which the cumula-
tive costs are sensitive, it is important to note that the overall 
trend of the results (a negative budget impact for GGS), does 
not change in the scenario and sensitivity analysis, when 
these rates are varied across a clinically relevant set of values. 
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Conclusion
From the perspective of the US IDS, GGS can be cost sav-
ing over the 6-year episode of care by obviating the need 
for repeated and costly invasive TGR surgical lengthenings 
and their associated complications, particularly deep SSIs. 
Compared with MCGR, GGS can be cost saving due to a 
comparable rod fracture and deep SSI rate and a substantially 
reduced construct cost. Further analyses focusing strictly on 
current generation technologies and accounting for HRQoL 
of children and their caregivers should be considered for 
future research.
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